Aspira Pathlab & Diagnostics Ltd. Hits Upper Circuit for the 2nd Straight Session on BSE, 22 September 2026

On 22 September 2026, Aspira Pathlab & Diagnostics Ltd. (ASPIRA) hit the upper circuit on BSE at Rs 126.78, a 4.99% positive move from the previous close of Rs 120.75. The company's market cap stood at Rs 124.29 crore. The upper circuit price for the session was Rs 126.78.

The move was driven by buying interest against the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Key Takeaways

• Aspira Pathlab & Diagnostics Ltd. (ASPIRA) hit the upper circuit on BSE at Rs 126.78 on 22 September 2026.
• The session move was +4.99% against a previous close of Rs 120.75.
• Market capitalisation stood at Rs 124.29 crore with a PE ratio of 51.81.
• This is the 2nd straight session at the upper circuit, with the run starting on 21 September 2026.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric	Value
Stock	Aspira Pathlab & Diagnostics Ltd.
Current Price / LTP	Rs 126.78
Day Move	4.99%
Previous Close	Rs 120.75
Day Open	Rs 126.78
Day High	Rs 126.78
Day Low	Rs 126.78
Upper Circuit Price	Rs 126.78
Upper Circuit Limit	Rs 126.78
Market Cap	Rs 124.29 crore
Selected Exchange	BSE
PE Ratio	51.81

All figures above are as of 22 September 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Aspira Pathlab & Diagnostics Ltd. opened at Rs 126.78 on BSE, compared with a previous close of Rs 120.75. During the session, the stock traded between Rs 126.78 and Rs 126.78 before touching the upper circuit price of Rs 126.78.

The absolute day change was Rs 6.03, while the percentage move was 4.99%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range, and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 126.78, which is the level the price reached.

The Upper Circuit Streak So Far

This is session 2 of an unbroken run for Aspira Pathlab & Diagnostics Ltd. The streak began on 21 September 2026, from a base price of Rs 115. Across the run the stock has moved 10.24% in total.

A repeated upper circuit matters more than a single one. It says the order book has stayed one-sided across multiple sessions rather than reacting to a single day of news, and for anyone holding the stock it means the price on screen has been hard to trade at for several days running.

This page is the running record for the streak and is updated each session rather than being replaced by a fresh article. That keeps one address for the event instead of splitting the same story across competing pages.

Why Aspira Pathlab & Diagnostics Ltd. Hit Upper Circuit

Aspira Pathlab & Diagnostics Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the upper circuit level of Rs 126.78.

What the Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Aspira Pathlab & Diagnostics Ltd., the captured upper circuit price was Rs 126.78 on 22 September 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Aspira Pathlab & Diagnostics Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Aspira Pathlab & Diagnostics Ltd., PE ratio was 51.81, PB ratio was 9.84, book value was Rs 12.28, EPS was 2.33, ROE was 18.13%, ROCE was 19.27%, dividend yield was 0% and debt-to-assets ratio was 0.1, on a market cap of Rs 124.29 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

A PB ratio above 1 means the market price was above the reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Aspira Pathlab & Diagnostics Ltd. belongs to the Hospital & Healthcare Services industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company	Market Cap	PE	PB	ROE
KMC Speciality Hospitals (India) Ltd.	Rs 2616.7 crore	46.92	11.53	31.61%
Dr Agarwals Eye Hospital Ltd.	Rs 2544.8 crore	33.39	6.88	36.29%
Krsnaa Diagnostics Ltd.	Rs 1756.55 crore	18.48	1.82	10.02%
SURAKSHA DIAGNOSTIC LIMITED	Rs 1750.17 crore	50.87	7.1	13.93%
Shalby Ltd.	Rs 1488.91 crore	38.07	1.47	6.31%

Several of these peers are far larger by market capitalisation than Aspira Pathlab & Diagnostics Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Aspira Pathlab & Diagnostics Ltd.'s PE ratio was 51.81, compared with an available peer/sector PE average of 37.55, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical and Ownership Snapshot

The technical snapshot adds context: RSI was 75.98, the 50-day moving average was 95.79 and the 200-day moving average was 88.46.

Shareholding details were not available in the latest market dataset, so no conclusion is drawn about promoter, institutional, or public-shareholder activity.

What Readers Should Know

The main confirmed fact is that Aspira Pathlab & Diagnostics Ltd. hit the upper circuit on BSE at Rs 126.78 on 22 September 2026, with a 4.99% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Aspira Pathlab & Diagnostics Ltd. hit upper circuit on 22 September 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

How many sessions has Aspira Pathlab & Diagnostics Ltd. hit upper circuit in a row?

This is session 2 of the current run, which began on 21 September 2026. This page is updated each session rather than replaced with a new article.

What was ASPIRA share price on 22 September 2026?

The last traded price used in this article was Rs 126.78 on BSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for ASPIRA?

The upper circuit price was Rs 126.78. The stated exchange upper circuit limit was Rs 126.78. The event numbers in this article are aligned to BSE.

What is Aspira Pathlab & Diagnostics Ltd.'s market cap and PE ratio?

Aspira Pathlab & Diagnostics Ltd.'s market cap was Rs 124.29 crore. PE ratio was 51.81.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 22 September 2026.

Does hitting an upper circuit mean Aspira Pathlab & Diagnostics Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Aspira Pathlab & Diagnostics Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Aspira Pathlab & Diagnostics Ltd. the stated limit was Rs 126.78. For this session, Aspira Pathlab & Diagnostics Ltd. moved 4.99%.

Footer Disclosure

This article is for informational purposes only and does not constitute investment advice. Research services are provided by Uniapps Investment Adviser Pvt. Ltd., a wholly owned subsidiary of Univest, SEBI RIA registration number INA000017639.